BridgeBio Pharma, Inc. logo BBIO - BridgeBio Pharma, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 25
HOLD 3
SELL 0
STRONG
SELL 0
| PRICE TARGET: $115.18 DETAILS
HIGH: $156.00
LOW: $97.00
MEDIAN: $110.00
CONSENSUS: $115.18
UPSIDE: 77.36%

Stock News

Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)

Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Taiwan Semiconductor Manufacturing stock on September 22nd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF

Oct 14, 2026 12:11 AM • defenseworld.net
BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

BridgeBio Pharma maintains a "Strong Buy" rating, driven by robust revenue growth and multiple late-stage pipeline catalysts. The company delivered Q2 2026 net revenues of $243.7M, up from the prior year's $110.6M, outperforming despite competition. Three NDA submissions—BBP-418, oral infigratinib, and encaleret—are under Priority Review, with PDUFA dates spanning late 2026 to mid-2027.

Oct 13, 2026 05:00 AM • seekingalpha.com
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records

Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records

- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U. S. electronic health record database, acoramidis was associated with a statistically significant 18% lower risk of a composite of death, all-cause hospitalization, new-onset atrial fibrillation, and diuretic intensification versus tafamidis (HR 0.

Oct 11, 2026 10:30 AM • globenewswire.com
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) will be shared at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place in Boston, Massachusetts on October 9-12, 2026.

Oct 06, 2026 12:01 PM • globenewswire.com
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one oral presentation, three rapid-fire oral presentations, and six poster presentations on acoramidis in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2026, taking place in Phoenix, Arizona on October 9-12, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

Oct 06, 2026 12:01 PM • globenewswire.com
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versus 40% in the placebo arm (p=0.0248); HS troponin I, a blood marker of heart muscle injury, declined more with BBP-418 than placebo (LS mean difference -17.8 ng/L; 95% CI: -35.1 to -0.5; p=0.0443)

Oct 05, 2026 03:30 AM • globenewswire.com
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status

BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status

BridgeBio Pharma (NASDAQ: BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a Bernstein discussion. Trimarchi said the company's strategy centers on developing medicines for genetic diseases with substantial unmet need, particularly where a genetic mechanism can be

Sep 26, 2026 12:03 AM • defenseworld.net
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting improved clinical stability of acoramidis over tafamidis

Sep 23, 2026 03:47 AM • globenewswire.com
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on September 18, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 63,009 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

Sep 18, 2026 12:01 PM • globenewswire.com
BridgeBio Pharma: Attruby Peak Sales Set To Rise

BridgeBio Pharma: Attruby Peak Sales Set To Rise

BridgeBio pharma has delivered multiple clinical and commercial successes, yet shares have repeatedly sold off after positive catalysts. Infigratinib's dwarfism trial outperformed the market leader, and Attruby continues to beat sales estimates, with management now guiding higher peak sales. Recent competitor setbacks and new data on Attruby's kidney benefits and hospital day reduction further strengthen BBIO's commercial outlook.

Sep 10, 2026 04:25 AM • seekingalpha.com

Price Targets